MiNK Therapeutics (NASDAQ: INKT) saw its shares spike 80% on Tuesday after unveiling a collaboration with C-Further to develop a PRAME-targeted iNKT cell therapy aimed at pediatric cancers. The deal centers on advancing an engineered T cell receptor (TCR) invariant natural killer T cell therapy directed at PRAME, a tumor-associated antigen present in multiple childhood malignancies.
Under the terms of the agreement, MiNK will receive approximately $1.1 million in non-dilutive funding to support IND-enabling development activities for its PRAME-TCR-iNKT candidate. The pact also provides for a double-digit share of potential downstream commercial revenues, with payments tied to the achievement of defined scientific milestones through preclinical candidate nomination and translational development stages.
The program will be advanced as part of C-Further, an international pediatric oncology therapeutics consortium. The initiative is one of the first selected by the consortium, which is enabled by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity. The consortium’s stated focus is accelerating immunotherapies for children with cancers that have limited treatment options.
MiNK’s iNKT platform is positioned as an allogeneic, off-the-shelf approach derived from healthy donors. According to the company’s program description, iNKT cells manufactured in advance can be delivered without HLA matching or the need for lymphodepleting chemotherapy. As part of the collaboration, MiNK will act as the lead industry partner while investigators at the University of Southampton will perform preclinical studies to assess anti-tumor activity and safety across pediatric cancer models.
The collaboration is non-exclusive, enabling MiNK to continue developing its iNKT platform independently for other oncology indications and in additional partnerships. Payments under the arrangement will be milestone-dependent, supporting the program through IND-enabling and translational development activities.
The targeted antigen PRAME is cited in the agreement as being expressed across several pediatric malignancies, including sarcomas, acute myeloid leukemia and medulloblastoma. The preclinical work at the University of Southampton is intended to evaluate both anti-tumor efficacy and safety in models representative of those diseases.
Market reaction to the announcement was swift, with the company’s shares surging following disclosure of the collaboration and the funding provisions. The structure of the deal - combining non-dilutive support, milestone-based payments and a potential revenue share - reflects a development-oriented partnership model intended to de-risk early-stage programs while preserving the company’s ability to pursue other opportunities.